B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Manager – Global ICSR Management

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's
Remote in Brazil
RemoteTravel required: 5%.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A minimum bachelor's degree in life sciences, clinical medicine, nursing, pharmacy, or another health-care professional field, or an equivalent combination of relevant education or professional experience.
  • At least five years of experience in drug safety/pharmacovigilance or relevant clinical experience, including training.
  • Strong understanding of global regulatory requirements, including ICH, GVP, FDA 21 CFR 312.32 and 314.80, GCP, NMPA Announcement No. 66 (2018), and the PAL of PRC (December 2019), for capture and submission of pharmacovigilance individual case safety reports and aggregate safety reports to FDA, CDE/NMPA, EMA, MHRA, and other global regulatory authorities or national competent authorities.
  • Proficiency in databases and case-processing activities, including data acquisition/intake, triage, coding, narrative construction, and due diligence.
  • Clinical knowledge of therapeutic-area patient populations and drug classes.
  • Experience using effective project- and time-management strategies to provide high-quality deliverables on time.
  • Ability to oversee team deliverables and represent functional responsibilities in audits and inspections.
  • Strong problem-solving skills, results orientation, and attention to detail.
  • Awareness of global cultures.
  • Fluency in English.
  • Ability to use the Argus safety database and other required platforms, Microsoft Office, Excel, PowerPoint, and Visio.
Responsibilities
  • Monitor triage, case processing, and quality control of individual case safety reports to ensure timely completion, and assist with execution when needed.
  • Oversee, analyze, and drive changes to the SAE reconciliation process.
  • Support SAE reconciliation between safety and clinical databases.
  • Track SAE reconciliation to ensure completion and adherence to internal and external timelines, and resolve or escalate issues.
  • Review SAE reconciliation plans.
  • Monitor quality and compliance key performance indicators or metrics.
  • Define quality and compliance key performance indicators or metrics with the Process Excellence team.
  • Generate quality and compliance metrics to meet internal and external timelines.
  • Analyze and resolve quality or compliance metric issues, including root-cause analysis and late-case investigation, and determine corrective actions.
  • Monitor productivity and volume key performance indicators or metrics.
  • Define and generate productivity and volume key performance indicators or metrics.
  • Analyze and resolve productivity issues.
  • Manage execution of continuous-improvement opportunities within ICSR Management with support from the senior manager.
  • Serve as business lead for process excellence, continuous improvement, productivity, and technology-efficiency initiatives with support from the senior manager.
  • Review ICSR workflow to ensure cases are completed within internal and external timelines.
  • Resolve or escalate case-prioritization and case-processing questions.
  • Balance team workload and ensure target key performance indicators are met.
  • Make process decisions on escalated issues regarding operational policies, standard operating procedures, and work instructions.
  • Contribute to changes in operational policies, standard operating procedures, and work instructions.
  • Analyze and drive changes to existing processes and procedures.
  • Assist in creating new procedural documents with support from the senior manager.
  • Act as a subject-matter expert in audits and inspections with support from the senior manager.
  • Execute audit- and inspection-readiness activities.
  • Communicate signed pharmacovigilance agreement or contract information to the team.
  • Lead critical process or subprocess areas and project initiatives within the GPS organization.
  • Lead or participate as an ICSR Management subject-matter expert on cross-functional projects outside the GPS organization, as needed.
  • Deliver training to new team members.
  • Develop and update training materials.
  • Provide the line manager with feedback for review about new team members' onboarding status.
  • Support resolution of new-team-member issues or escalate them to the line manager.
  • Execute study-configuration testing in the safety database as needed.
  • Oversee team deliverables and supervise staff across multiple GPS sites as business needs require.
  • Mentor team members and provide growth and development opportunities.
  • Contribute to staff recruitment.
Desired Qualifications
  • Pharmaceutical or biotechnology industry experience.
  • An advanced degree.
  • Digital skills.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.